AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
HIV-associated neuropathy pain eased by Gabapentin. (Dose-Defendant Response).
SAN DIEGO -- Gabapentin relieves the pain of HIV-associated neuropathy in a dose-dependent fashion, Dr. Michael C. Rowbotham reported at the 10th World Congress on Pain.
Gabapentin treatment also improved sleep, mood, and some quality of life measures, but there was no difference in those measures between patients taking either 900 or 3,600 mg/day he said during a poster session.
In a double-blind, parallel-group trial, 58 subjects were randomized to receive either the high or the low dose of gabapentin. They started by taking either 1,200 or 300 mg/day respectively, and were titrated up to the target doses over 3 weeks. The patients then stayed at the target dose for 1 week.
At baseline, patients in the high-dose group had a mean pain score of 6.5 on a scale of 0 to 10. The patients in the low-dose group had a mean starting pain score of 6.1. Both groups experienced a progressive reduction in pain throughout the study's duration.
By the study's fourth and final week, the mean scores had dropped to 3.5 in the high-dose group and 4 in the low-dose group, for a 46% decline in pain among those receiving the high dose and a 30% decline in those receiving the low dose. Pain scores were still declining when the study ended, said Dr. Rowbotham, professor of clinical neurology ...
- Axonyx Announces Results of Interim Analysis of Beta- Amyloid Trial; Data Meet...
- Press release article from: Business Wire March 12, 2005 700+ words
...groups achieved statistical significance. However, there was sufficient information to conclude that enrollment to the 15mg dose group was justified, but not to the 10mg group. Completion of patient enrollment of this trial is expected in the second quarter...
- Injection port features reduced recession.(Injection Port 4 from Medi-Dose...
- Magazine article from: McKnight's Long-Term Care News April 14, 2000 700+ words
EPS(R) Inc., a member of the Medi-Dose(r) Group, introduces the latex-free Injection Port 4. According to the manufacturer, the device is indicated for use with catheters, extension sets and reconstruction devices. Features include reduced recession of the port, a transparent bottom to allow for
- Genmab to Present HuMax-CD4 Data at the Society for Investigative Dermatology...
- Press release article from: PR Newswire February 18, 2004 700+ words
Genmab A/S announced today it will present data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th Annual Meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4
- Nevirapine regimen reduces risk of HIV transmission from breast-feeding--at...
- Magazine article from: International Family Planning Perspectives Doskoch, P. September 1, 2008 700+ words
...become infected with HIV was significantly...proportion in the single-dose group (3%vs. 5...than in the single-dose group (1% vs. 4...that included both HIV transmission and...in the extended-dose group than in the single...
- Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry...
- Press release article from: Business Wire May 30, 2006 700+ words
...viral load with the high dose group showing the most difference...patients experiencing HIV drug resistance. The...treatment-experience HIV patients, assessed SP01A...effect on viral load in HIV-1 positive individuals...difference between the high dose group (800mg/day) and ...
- TMC114 Expanded Access Program for People Living with HIV/AIDS to Begin...
- Press release article from: PR Newswire June 14, 2005 700+ words
...prevent the replication of HIV in the body. The TMC114...Patients in the highest dose group, 600mg/100mg BID, experienced...mean reduction in plasma HIV RNA of -1.85 log10...ranged from 30% (lowest dose group) to 47% (highest dose...
- Reports on HIV/AIDS findings from University of Alabama provide new insights.
- Newspaper article from: AIDS Vaccine Week September 15, 2008 700+ words
...characterize the HIV-1-specific T...i.m. (high-dose group C) each time. Each...seen in the high-dose group than in the other...only in the high-dose group," wrote A. Bansal...Alabama (see also HIV/AIDS). The researchers...
- Gilead Sciences Presents 48-Week Phase II Safety and Efficacy Results for...
- Press release article from: Business Wire April 16, 2000 700+ words
...tenofovir DF. The mean change in HIV RNA from baseline for patients...weeks had a mean change in HIV RNA of -0.71 log10 at 48...patients (20%) in the 300 mg dose group, 12 patients (24%) in the 150 mg dose group, 14 patients (26%) in the...